Contact dermatitis-like cutaneous leishmaniasis in a Libyan HIV patient
© Al-Dwibe et al.; licensee BioMed Central Ltd. 2014
Received: 20 April 2014
Accepted: 7 August 2014
Published: 29 August 2014
Cutaneous leishmaniasis (CL) is one of the common tropical protozoal diseases caused by various Leishmania species, and transmitted by the sand-fly vectors, Phlebotomus and Lutzomyia species. Herein, we report for the first time a case of CL that presented as large eczematous plaques occurring on the dorsi of both feet in a Libyan drug addicted, alcoholic patient with HIV infection.
A 34 year-old HIV-positive, alcoholic, drug addicted Libyan male presented to us with a history of a non-itchy skin lesions on the dorsi of both feet of 5-weeks duration. Systemic and topical antibiotics were given without improvement. Diagnosis of this patient was confirmed by observation of Leishmania amastigote bodies in stained slit-skin smear skin biopsy. After parenteral administration of sodium stiboglyconate (Pentostam) (20 mg/kg/day) for 28 days the lesions did not show any marked improvement. Concurrently, combination therapy of oral rifampicin (600 mg/day) and isoniazide (300 mg/day) was given for 8 weeks. Complete healing of lesions was achieved after this treatment and skin-slit smears turned negative.
Localized cutaneous leishmaniasis should be remembered in deferential diagnosis of unresponsive contact dermatitis especially for HIV-positive patients in CL endemic areas.
This patient was not responding to Pentostam therapy, which is not very common in Libya. Interestingly, combination of oral rifampicin (600 mg/day) and isoniazide (300 mg/day) can be a successful alternative therapy.
A 34 year-old HIV-positive, alcoholic, drug addicted Libyan male presented to us with a history of non itchy skin lesions on the dorsi of both feet of 5-weeks duration. The lesions started as small non itchy papules which gradually increased in size and then ulcerated with offensive odour. The patient applied warm onion to treat the lesions, which turned painful and for that he sought medical advice. Systemic and topical antibiotics were given without improvement. The patient denied history of trauma, insect bite, unbalanced diabetes, or allergic diseases and no family history of the same illness.
Cutaneous leishmaniasis (CL) is one of the common tropical protozoal diseases caused by various Leishmania species, and transmitted by the sand-fly vector of Phlebotomus and Lutzomyia species. About 1.5 million new cases are reported each year, and over 350 million people live in areas of active parasite transmission [2–5]. CL is a major public health problem in Libya caused by L. major and L. tropica. Leishmania species can cause a wide spectrum of cutaneous lesions such as localized cutaneous, muco-cutaneous, diffuse cutaneous, or post-kala-azar dermal leishmaniasis [7, 8]. In HIV-positive patients: asymptomatic and mucosal leishmaniasis has been reported in addition to other usual types . However, HIV-positive intravenous drug users (IVDUs) can be infected with Leishmania by sharing of contaminated syringes and needles . Clinical variation of leishmaniasis –HIV co-infection is determined by parasite species and host cell mediated immunity (CMI) response . Recently, clinical variants of CL with or without HIV co-infection have been reported such as; sporotrichoid, psoriasiform, warty, erysipeloid, impetigo like, cold cellulitis, zosteriform, acneiform, and eczematoid variant [10–12]. The incidence of eczematoid variant of localized CL seems not to be very common and reported to be 2.3% .
Herein, we report for the first time a case of Pentostam unresponsive CL that presented as large eczematous plaques occurring on the dorsi of both feet in a Libyan drug addicted patient with HIV infection. Localized CL typically presented as papules, nodules, plaques, ulcerated or crusted nodules. A contact dermatitis like morphology of localized CL lesions is unusual. Diagnosis of CL was confirmed by observation of parasites in stained slit-skin smears. This patient was unresponsive to Pentostam, which is not very common in Libya. Combination therapy of oral rifampicin and isoniazide completely cured the lesions. This combination therapy is used in Libya to treat cutaneous tuberculosis and to treat CL cases unresponsive to parenteral administration of Pentostam . A previous study by Peters et al. descried a striking remission of CL in a Brazilian patient by using this combination. Small scale studies on oral rifampicin treatment of CL have shown a healing rate of 73.9%, 75% and 83.3% [14–16] respectively. However, no clinical trial was carried out to approve combination therapy of rifampicin and isoniazide in treatment of CL .
The patient denied insect bites though he came from Gabel Garby where CL is endemic, possibly the patient was unnoticeably bitten during drug and alcohol intake.
According to ethical approval of this study, the patient agreed to publish his photos and case history anonymously. Written informed consent was obtained from the patient. The study was revised and approved by (Research Ethics committee, University of Tripoli, Libya).
The learning points from this short report is that localized cutaneous leishmaniasis should be considered in differential diagnosis of unresponsive contact dermatitis especially for HIV-positive patients in CL endemic areas. A combination of oral rifampicin (600 mg/day) and isoniazide (300 mg/day) can be successful alternative therapy for Pentostam unresponcive CL patients in Libya. However, this combination therapy has to be assessed at a larger scale.
- Schonian G, Nasereddin A, Dinse N, Schweynoch C, Schallig HD, Presber W, Jaffe CL: PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Micr Infect Dis. 2003, 47 (1): 349-358. 10.1016/S0732-8893(03)00093-2.View ArticleGoogle Scholar
- Chaudhary RG, Bilimoria FE, Katare SK: Diffuse cutaneous leishmaniasis: co-infection with human immunodeficiency virus (HIV). Indian J Dermatol Venereol Leprol. 2008, 74 (6): 641-643. 10.4103/0378-6323.45111.View ArticlePubMedGoogle Scholar
- Hepburn NC: Cutaneous leishmaniasis: an overview. J Postgrad Med. 2003, 49 (1): 50-54. 10.4103/0022-3859.928.View ArticlePubMedGoogle Scholar
- WHO technical report series. Control of the Leishmaniases. 2010, (949):xii-xiii, 1–186, back coverGoogle Scholar
- Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M: Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012, 7 (5): e35671-10.1371/journal.pone.0035671.PubMed CentralView ArticlePubMedGoogle Scholar
- Amro A, Gashout A, Al-Dwibe H, Zahangir Alam M, Annajar B, Hamarsheh O, Shubar H, Schonian G: First molecular epidemiological study of cutaneous leishmaniasis in Libya. PLoS NTD. 2012, 6 (6): e1700-Google Scholar
- Manzur A, Butt UA: Atypical cutaneous leishmaniasis resembling eczema on the foot. Dermatol Online J. 2006, 12 (3): 18-PubMedGoogle Scholar
- WHO publications. Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region. 2012, 9-18.Google Scholar
- Puig L, Pradinaud R: Leishmania and HIV co-infection: dermatological manifestations. Ann Trop Med Parasitol. 2003, 97 (Suppl 1): 107-114.View ArticlePubMedGoogle Scholar
- Kubba R, Al-Gindan Y, el-Hassan AM, Omer AH: Clinical diagnosis of cutaneous leishmaniasis (oriental sore). J Am Acad Dermatol. 1987, 16 (6): 1183-1189. 10.1016/S0190-9622(87)70155-8.View ArticlePubMedGoogle Scholar
- Momeni AZ, Aminjavaheri M: Clinical picture of cutaneous leishmaniasis in Isfahan. Iran Int J Parasitol. 1994, 33 (4): 260-265.Google Scholar
- Cabello I, Caraballo A, Millan Y: Leishmaniasis in the genital area. Rev Inst Med Trop Sao Paulo. 2002, 44 (2): 105-107. 10.1590/S0036-46652002000200009.View ArticlePubMedGoogle Scholar
- Peters W, Lainson R, Shaw JJ, Robinson BL, Leao AF: Potentiating action of rifampicin and isoniazid against Leishmania mexicana amazonensis. Lancet. 1981, 1 (8230): 1122-1124.View ArticlePubMedGoogle Scholar
- Even-Paz Z, Weinrauch L, Livshin R, El-On J, Greenblatt CL: Rifampicin treatment of cutaneous leishmaniasis. Int J Dermatol. 1982, 21 (2): 110-112. 10.1111/j.1365-4362.1982.tb00517.x.View ArticlePubMedGoogle Scholar
- Kochar DK, Aseri S, Sharma BV, Bumb RA, Mehta RD, Purohit SK: The role of rifampicin in the management of cutaneous leishmaniasis. QJM. 2000, 93 (11): 733-737. 10.1093/qjmed/93.11.733.View ArticlePubMedGoogle Scholar
- Bumb RA, Mehta RD: Oral rifampicin in cases of cutaneous leishmaniasis with multiple lesions (a pilot study). Indian J Dermatol Venereol Leprol. 2002, 68 (5): 272-PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.